Location of Repository

Hla-Dm Recognizes the Flexible Conformation of Major Histocompatibility Complex Class II

By Chih-Ling Chou and Scheherazade Sadegh-Nasseri


DM facilitates formation of high affinity complexes of peptide–major histocompatibility complex (MHC) by release of class II MHC–associated invariant chain peptide (CLIP). This has been proposed to occur through discrimination of complex stability. By probing kinetic and conformational intermediates of the wild-type and mutant human histocompatibility leukocyte antigen (HLA)-DR1–peptide complexes, and examining their reactivities with DM, we propose that DM interacts with the flexible hydrophobic pocket 1 of DR1 and converts the molecule into a conformation that is highly peptide receptive. A more rigid conformation, generated upon filling of pocket 1, is less susceptible to DM effects. Thus, DM edits peptide–MHC by recognition of the flexibility rather than stability of the complex

Topics: Original Article
Publisher: The Rockefeller University Press
OAI identifier: oai:pubmedcentral.nih.gov:2213500
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (1997). A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes.
    2. (1995). A general model of invariant chain association with class II major histocompatibility complex proteins.
    3. (1989). A kinetic intermediate in the reaction of an antigenic peptide and I-Ek.
    4. (1991). A role for peptide in determining MHC class II structure.
    5. (1998). Altered antigen presentation in mice lacking H2-O.
    6. (1994). Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes.
    7. (1994). Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.
    8. (1990). Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes.
    9. (1998). Determination of binding constants by equilibrium titration with circulating sample in a surface plasmon resonance biosensor.
    10. (1993). Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity.
    11. (2000). DM determines the cryptic and immunodominant fate of T cell epitopes.
    12. (1995). DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
    13. (1996). Editing of the HLA-DRpeptide repertoire by HLA-DM.
    14. (1991). Energy transfer between two peptides bound to one MHC class II molecule.
    15. (1996). Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
    16. Formation of a highly peptide-receptive state of class II MHC.
    17. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations.
    18. (1997). HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH.
    19. (1995). HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
    20. (1996). HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    21. (1992). HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
    22. (1996). HLADM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules.
    23. (1992). How MHC class II molecules work: peptide-dependent completion of protein folding.
    24. (1996). Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    25. (2000). Impaired immune responses and altered peptide repertoire in tapasindeficient mice.
    26. (1997). Interaction between HLADM and HLA-DR involves regions that undergo conformational changes at lysosomal pH.
    27. (1996). Kinetic analysis of peptide loading onto HLADR molecules mediated by HLA-DM.
    28. (1995). Measuring interactions of MHC class I molecules using surface plasmon resonance.
    29. (1995). Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    30. (1994). MHC class II function preserved by low-affinity peptide interactions preceding stable binding.
    31. (1991). MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding.
    32. (1998). Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization.
    33. (1993). Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules.
    34. (1996). Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules.
    35. (1999). Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1.
    36. (1999). Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides.
    37. Structural intermediates in the reactions of antigenic peptides with MHC molecules.
    38. (1996). Structures of an MHC class II molecule with covalently bound single peptides.
    39. (1994). The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy.
    40. (1992). The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide.
    41. the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1.
    42. (1998). The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed.
    43. (1995). The requirement for DM in class II– restricted antigen presentation and SDS-stable dimer formation is allele and species dependent.
    44. (1998). The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.